Non-steroidal anti-inflammatory drugs and bladder cancer prevention

Abstract

Inclusion of phenacetin among 'proven' human carcinogens by the IARC in 1987, raised concerns about the carcinogenic potential of acetaminophen, its major metabolite. Acetaminophen has been implicated as a possible causal agent in the development of cancer of the renal pelvis. The bladder and renal pelvis, which derive from the same embryological structure, share the same transitional type of epithelium. Past studies have been inconclusive on the possible relationship among these analgesics and bladder cancer but no large, highly detailed study of this association has been conducted. A population-based case-control study conducted in Los Angeles, California, involved 1514 incident bladder cancer cases and an equal number of controls who were matched to the index cases by sex, date of birth (within 5 years) and race. Detailed information on medication use and prior medical conditions was collected through in-person interviews. Regular use of analgesics was not associated with an increased risk of bladder cancer in either men or women. In fact, compared with non- or irregular users, regular analgesic users were at a decreased risk of bladder cancer overall (odds ratio (OR) = 0.81, 95% confidence interval (CI) = 0.68-0.96). However, there were clear differences in both the direction and strength of the associations between the different formulation classes of analgesics and bladder cancer risk. Intake of phenacetin was positively related to bladder cancer risk in a dose-dependent manner while intake of its major metabolite in humans, acetaminophen, was unrelated to risk. Intake of all classes of NSAIDs, except pyrazolon derivatives, were negatively associated with bladder cancer risk, with suggestive evidence that the protective effect varies in strength by subcategories of formulation. Acetic acids seemed to exhibit the strongest protective effect, whereas aspirin/other salicylic acids and oxicam showed the weakest protection.

References 42

1. 1.

   Angervall L., Bengtsson U., Zetterlund C. G., Zsigmond M. Renal pelvic carcinoma in a Swedish district with abuse of a phenacetin-containing drug. Br J Urol. 1969;41(4):401-405.

   Not in our library10.1111/j.1464-410x.1969.tb09939.x

2. 2.

   Boring C. C., Squires T. S., Tong T., Montgomery S. Cancer statistics, 1994. CA Cancer J Clin. 1994;44(1):7-26.

   Not in our library10.3322/canjclin.44.1.7

3. 3.

   Cohen S. M., Hasegawa R., Sakata T., Johansson S. L. Effect of aspirin on urinary bladder carcinogenesis initiated with N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide in rats. Cancer Res. 1989;49(2):372-377.

   Not in our library

4. 4.

   Denda A., Endoh T., Kitayama W., Tang Q., Noguchi O., Kobayashi Y., Akai H., Okajima E., Tsujiuchi T., Tsutsumi M. Inhibition by piroxicam of oxidative DNA damage, liver cirrhosis and development of enzyme-altered nodules caused by a choline-deficient, L-amino acid-defined diet in rats. Carcinogenesis. 1997;18(10):1921-1930.

   Not in our library10.1093/carcin/18.10.1921

5. 5.

   Derby L. E., Jick H. Acetaminophen and renal and bladder cancer. Epidemiology. 1996;7(4):358-362.

   Not in our library10.1097/00001648-199607000-00004

6. 6.

   DuBois R. N., Radhika A., Reddy B. S., Entingh A. J. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology. 1996;110(4):1259-1262.

   Not in our library10.1053/gast.1996.v110.pm8613017

7. 7.

   Flaks B., Flaks A., Shaw A. P. Induction by paracetamol of bladder and liver tumours in the rat. Effects on hepatocyte fine structure. Acta Pathol Microbiol Immunol Scand A. 1985;93(6):367-377.

   Not in our library10.1111/j.1699-0463.1985.tb03964.x

8. 8.

   Fokkens W. Phenacetin abuse related to bladder cancer. Environ Res. 1979;20(1):192-198.

   Not in our library10.1016/0013-9351(79)90097-5

9. 9.

   Gago-Dominguez M., Yuan J. M., Castelao J. E., Ross R. K., Yu M. C. Regular use of analgesics is a risk factor for renal cell carcinoma. Br J Cancer. 1999;81(3):542-548.

   Not in our library10.1038/sj.bjc.6690728

10. 10.

    Giardiello F. M., Offerhaus G. J., DuBois R. N. The role of nonsteroidal anti-inflammatory drugs in colorectal cancer prevention. Eur J Cancer. 1995;31A(7-8):1071-1076.

    Not in our library10.1016/0959-8049(95)00137-8

11. 11.

    Giovannucci E., Egan K. M., Hunter D. J., Stampfer M. J., Colditz G. A., Willett W. C., Speizer F. E. Aspirin and the risk of colorectal cancer in women. N Engl J Med. 1995;333(10):609-614.

    Not in our library10.1056/nejm199509073331001

12. 12.

    Grubbs C. J., Juliana M. M., Eto I., Casebolt T., Whitaker L. M., Canfield G. J., Manczak M., Steele V. E., Kelloff G. J. Chemoprevention by indomethacin of N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder tumors. Anticancer Res. 1993;13(1):33-36.

    Not in our library

13. 13.

    Herschman H. R. Regulation of prostaglandin synthase-1 and prostaglandin synthase-2. Cancer Metastasis Rev. 1994;13(3-4):241-256.

    Not in our library10.1007/bf00666095

14. 14.

    Hiraga K., Fujii T. Carcinogenicity testing of acetaminophen in F344 rats. Jpn J Cancer Res. 1985;76(2):79-85.

    Not in our library

15. 15.

    Hultengren N., Lagergren C., Ljungqvist A. Carcinoma of the renal pelvis in renal papillary necrosis. Acta Chir Scand. 1965;130(4):314-320.

    Not in our library

16. 16.

    Johansson S. L. Carcinogenicity of analgesics: long-term treatment of Sprague-Dawley rats with phenacetin, phenazone, caffeine and paracetamol (acetamidophen). Int J Cancer. 1981;27(4):521-529.

    Not in our library10.1002/ijc.2910270416

17. 17.

    Johansson S., Wahlqvist L. Tumours of urinary bladder and ureter associated with abuse of phenacetin-containing analgesics. Acta Pathol Microbiol Scand A. 1977;85(6):768-774.

    Not in our library10.1111/j.1699-0463.1977.tb03892.x

18. 18.

    Kargman S. L., O'Neill G. P., Vickers P. J., Evans J. F., Mancini J. A., Jothy S. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res. 1995;55(12):2556-2559.

    Not in our library

19. 19.

    Kari F., Bucher J., Haseman J., Eustis S., Huff J. Long-term exposure to the anti-inflammatory agent phenylbutazone induces kidney tumors in rats and liver tumors in mice. Jpn J Cancer Res. 1995;86(3):252-263.

    Not in our library10.1111/j.1349-7006.1995.tb03048.x

20. 20.

    Kelloff G. J., Boone C. W., Crowell J. A., Steele V. E., Lubet R., Sigman C. C. Chemopreventive drug development: perspectives and progress. Cancer Epidemiol Biomarkers Prev. 1994;3(1):85-98.

    Not in our library

21. 21.

    Klän R., Knispel H. H., Meier T. Acetylsalicylic acid inhibition of n-butyl-(4-hydroxybutyl)nitrosamine-induced bladder carcinogenesis in rats. J Cancer Res Clin Oncol. 1993;119(8):482-485.

    Not in our library10.1007/bf01215929

22. 22.

    Kokmen E., Beard C. M., O'Brien P. C., Offord K. P., Kurland L. T. Is the incidence of dementing illness changing? A 25-year time trend study in Rochester, Minnesota (1960-1984). Neurology. 1993;43(10):1887-1892.

    Not in our library10.1212/wnl.43.10.1887

23. 23.

    Kune G. A., Kune S., Watson L. F. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res. 1988;48(15):4399-4404.

    Not in our library

24. 24.

    Liu X. H., Rose D. P. Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines. Cancer Res. 1996;56(22):5125-5127.

    Not in our library

25. 25.

    Lupulescu A. Prostaglandins, their inhibitors and cancer. Prostaglandins Leukot Essent Fatty Acids. 1996;54(2):83-94.

    Not in our library10.1016/s0952-3278(96)90064-2

26. 26.

    Marnett L. J. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res. 1992;52(20):5575-5589.

    Not in our library

27. 27.

    McCredie M., Ford J. M., Taylor J. S., Stewart J. H. Analgesics and cancer of the renal pelvis in New South Wales. Cancer. 1982;49(12):2617-2625.

    Not in our library10.1002/1097-0142(19820615)49:12<2617::aid-cncr2820491235>3.0.co;2-x

28. 28.

    McCredie M., Stewart J. H. Does paracetamol cause urothelial cancer or renal papillary necrosis? Nephron. 1988;49(4):296-300.

    Not in our library10.1159/000185079

29. 29.

    McCredie M., Stewart J. H., Ford J. M., MacLennan R. A. Phenacetin-containing analgesics and cancer of the bladder or renal pelvis in women. Br J Urol. 1983;55(2):220-224.

    Not in our library10.1111/j.1464-410x.1983.tb06561.x

30. 30.

    McGeer P. L., Schulzer M., McGeer E. G. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology. 1996;47(2):425-432.

    Not in our library10.1212/wnl.47.2.425

31. 31.

    Moon R. C., Detrisac C. J., Thomas C. F., Kelloff G. J. Chemoprevention of experimental bladder cancer. J Cell Biochem Suppl. 1992;16I:134-138.

    Not in our library10.1002/jcb.240501326

32. 32.

    Moon R. C., Kelloff G. J., Detrisac C. J., Steele V. E., Thomas C. F., Sigman C. C. Chemoprevention of OH-BBN-induced bladder cancer in mice by piroxicam. Carcinogenesis. 1993;14(7):1487-1489.

    Not in our library10.1093/carcin/14.7.1487

33. 33.

    Murai T., Mori S., Machino S., Hosono M., Takeuchi Y., Ohara T., Makino S., Takeda R., Hayashi Y., Iwata H. Induction of renal pelvic carcinoma by phenacetin in hydronephrosis-bearing rats of the SD/cShi strain. Cancer Res. 1993;53(18):4218-4223.

    Not in our library

34. 34.

    Murasaki G., Zenser T. V., Davis B. B., Cohen S. M. Inhibition by aspirin of N-[4-(5-nitro-2-furyl)-2-thiazolyl] formamide-induced bladder carcinogenesis and enhancement of forestomach carcinogenesis. Carcinogenesis. 1984;5(1):53-55.

    Not in our library10.1093/carcin/5.1.53

35. 35.

    Müller-Decker K., Scholz K., Marks F., Fürstenberger G. Differential expression of prostaglandin H synthase isozymes during multistage carcinogenesis in mouse epidermis. Mol Carcinog. 1995;12(1):31-41.

    Not in our library10.1002/mc.2940120106

36. 36.

    O'Neill G. P., Mancini J. A., Kargman S., Yergey J., Kwan M. Y., Falgueyret J. P., Abramovitz M., Kennedy B. P., Ouellet M., Cromlish W. Overexpression of human prostaglandin G/H synthase-1 and -2 by recombinant vaccinia virus: inhibition by nonsteroidal anti-inflammatory drugs and biosynthesis of 15-hydroxyeicosatetraenoic acid. Mol Pharmacol. 1994;45(2):245-254.

    Not in our library

37. 37.

    Okajima E., Denda A., Ozono S., Takahama M., Akai H., Sasaki Y., Kitayama W., Wakabayashi K., Konishi Y. Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine. Cancer Res. 1998;58(14):3028-3031.

    Not in our library

38. 38.

    Piper J. M., Tonascia J., Matanoski G. M. Heavy phenacetin use and bladder cancer in women aged 20 to 49 years. N Engl J Med. 1985;313(5):292-295.

    Not in our library10.1056/nejm198508013130504

39. 39.

    Rao K. V., Detrisac C. J., Steele V. E., Hawk E. T., Kelloff G. J., McCormick D. L. Differential activity of aspirin, ketoprofen and sulindac as cancer chemopreventive agents in the mouse urinary bladder. Carcinogenesis. 1996;17(7):1435-1438.

    Not in our library10.1093/carcin/17.7.1435

40. 40.

    Ristimäki A., Honkanen N., Jänkälä H., Sipponen P., Härkönen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 1997;57(7):1276-1280.

    Not in our library

Cited by papers we hold 5

• Associations between aspirin use and the risk of cancers: a meta-analysis of observational studies · 2018
  No notice
• Use of nonsteroidal anti-inflammatory drugs and bladder cancer risk: a meta-analysis of epidemiologic studies. · 2013
  Not checked
• Analgesic and anti-inflammatory drug use and risk of bladder cancer: a population based case control study · 2007
  Not checked
• A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin · 2003
  No notice
• Chronic immune activation and inflammation as the cause of malignancy · 2001
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.